CheckMate-577
Adjuvant Nivolumab in Resected Oesophageal/GEJ Cancer
Paciente / Población Intervención / Exposición Comparación Desenlace
In 794 patients with resected oesophageal/GEJ cancer and residual pathologic disease after neoadjuvant chemoradiation, adjuvant nivolumab for one year improved disease-free survival compared with placebo.
N
794
Diseño
Double-blind RCT
Desenlace
Disease-free survival
Relevancia
3
ResultadoDFS 22.4 vs 11.0 months (HR 0.69). Final OS 51.7 vs 35.3 months (HR 0.85; p=0.1064) — not statistically significant.
Kelly RJ, et al. N Engl J Med. 2021;384(13):1191-1203. 10.1056/NEJMoa2032125
Discusión y crítica
DFS-positive but OS-not-significant — a recurrent pattern in adjuvant immunotherapy trials. Counsel patients accordingly.